Design and Synthesis of Novel N-Acetylgalactosamine-Terminated Glycolipids for Targeting of Lipoproteins to the Hepatic Asialoglycoprotein Receptor-Reference-Cited by-同舟云学术

Design and Synthesis of Novel N-Acetylgalactosamine-Terminated Glycolipids for Targeting of Lipoproteins to the Hepatic Asialoglycoprotein Receptor

Published:2004-10-06 Issue:23 Volume:47 Page:5798-5808
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Rensen Patrick C. N.¹,van Leeuwen Steven H.¹,Sliedregt Leo A. J. M.¹,van Berkel Theo J. C.¹,Biessen Erik A. L.¹

Affiliation:

1. Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, University of Leiden, Gorlaeus Laboratory, P.O. Box 9502, 2300 RA Leiden, The Netherlands

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm049481d

Reference36 articles.

1. Case 45-1989

2. Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing Liver Gene Therapy: Enhanced Transduction with GalNAc-Bioconjugated rAAV Capsids;2024-07-25

2. Oligonucleotide therapies for nonalcoholic steatohepatitis;Molecular Therapy - Nucleic Acids;2024-06

3. RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects;Microorganisms;2024-03-17

4. RNA interference in the era of nucleic acid therapeutics;Nature Biotechnology;2024-02-26

5. Retreatment with HBV siRNA Results in Additional Reduction in HBV Antigenemia and Immune Stimulation in the AAV-HBV Mouse Model;Viruses;2024-02-23